Sagent Pharmaceuticals, Inc. 4
4 · Sagent Pharmaceuticals, Inc. · Filed Aug 31, 2016
Insider Transaction Report
Form 4
Greve Jeffrey W.
Vice President, Controller
Transactions
- Disposition to Issuer
Stock Option to Buy
2016-08-29$1.59/sh−8,865$14,095→ 0 totalExercise: $20.16Exp: 2024-02-18→ Common Stock (8,865 underlying) - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−4,962$107,924→ 0 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$5.30/sh−8,604$45,601→ 0 totalExercise: $16.45Exp: 2023-02-21→ Common Stock (8,604 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−10,507$75,020→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (10,507 underlying)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these restricted shares were canceled and converted into the right to receive $21.75 per share, without interest, less any applicable withholding taxes (the "Merger Consideration").
- [F2]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
- [F3]Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.
- [F4]Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration.